Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 11, Number 7—July 2005

West Nile Virus–associated Flaccid Paralysis

James J. Sejvar*Comments to Author , Amy V. Bode†, Anthony A. Marfin†, Grant L. Campbell†, David Ewing‡, Michael Mazowiecki‡, Pierre V. Pavot§, Joseph Schmitt¶, John Pape#, Brad J. Biggerstaff†, and Lyle R. Petersen†
Author affiliations: *Centers for Disease Control and Prevention, Atlanta, Georgia, USA; †Centers for Disease Control and Prevention, Fort Collins, Colorado, USA; ‡Centennial Neurology, Greeley, Colorado, USA; §Longmont Clinic, Longmont, Colorado, USA; ¶McKee Hospital, Loveland, Colorado, USA; #Colorado Department of Health and Environment, Denver, Colorado, USA

Main Article

Table 2

Presence of dysarthria/dysphagia, facial weakness, encephalitis, and immunocompromised status among patients with and without respiratory failure due to West Nile virus infection

Variable Respiratory failure
(N = 12*) No respiratory failure
(N = 20) Odds ratio p value†
Dysarthria/dysphagia 11 3 62 <0.0001
Immunocompromised status 4 0 Undefined 0.01
Encephalitis 12 5 Undefined <0.0001
Facial nerve weakness 6 5 3 0.25

*Includes 1 patient with respiratory weakness secondary to Guillain-Barré–like syndrome.
†Fisher exact test.

Main Article

Page created: April 23, 2012
Page updated: April 23, 2012
Page reviewed: April 23, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.